How an immune system regulator shifts the balance of immune cells
New findings may help scientists develop novel ways of tweaking the immune system to treat infections and disease
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
Their study, published today in eLife, reveals that cAMP shifts the type of immune system t-helper (Th) cells created in response to a threat by repressing gene transcription by key proteins. The findings may help scientists develop new ways of manipulating the immune system to treat diseases.
Th cells help the immune system identify infections and flag infected cells for destruction by killer T-cells. Previous studies had shown that low cAMP levels cause the immune system to produce more Th2-type cells, while high cAMP levels boost the production of Th17 cells. “In the current study, we dissected the molecular mechanisms by which cAMP levels regulate these Th responses,” says lead author Jihyung Lee, Assistant Project Scientist in Medicine at the University of California San Diego School of Medicine (UC San Diego), US.
Lee and the team showed that treating cells with cAMP reprograms Th2 cells to Th17 cells. It does this by suppressing IRF4 and KLF4, two transcription factors that turn on the genes needed to produce Th2 cells. The team then verified this by showing that mice genetically engineered to lack IRF4 have more Th17 cells. Treating these mice with IRF4 restored their Th2 cell levels.
“Our findings identify a new role for cAMP in immune system flexibility and may suggest new therapeutic approaches to control immune responses,” says senior author Eyal Raz, Director of the Center for Immunology, Inflammation, and Immune-mediated Disease at Guangzhou Medical University, China, and Emeritus Professor of Medicine at UC San Diego School of Medicine. “For example, drugs that boost cAMP levels may help people recover from bacterial infections by boosting the number of Th17 cells. Drugs that decrease cAMP levels may be helpful in treating parasitic infections, which require a more robust Th2 response.”
The results also suggest that drugs repressing IRF4 or KLF4 might be useful in, for example, treating blood cancers that emerge from immune cells called B-cells in the bone marrow.
The paper ‘Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses’ can be freely accessed online at https:/
Emily Packer, Senior Press Officer
eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours in science. We publish important research in all areas of the life and biomedical sciences, including Immunology and Inflammation, which is selected and evaluated by working scientists and made freely available online without delay. eLife also invests in innovation through open-source tool development to accelerate research communication and discovery. Our work is guided by the communities we serve. eLife is supported by the Howard Hughes Medical Institute, the Max Planck Society, the Wellcome Trust and the Knut and Alice Wallenberg Foundation. Learn more at https:/
To read the latest Immunology and Inflammation research published in eLife, visit https:/
Full list of funders and grant numbers:
Crohn’s and Colitis Foundation of America, National Natural Science Foundation of China, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, U.S. Department of Veterans Affairs, Deutsche Forschungsgemeinschaft
CCFA327206, NSFC81500017, R01AI113145, HD012303, CA196853, CA023100, DK063491, HL141999a, I01BX000130, NSFC81373128, NU 53/9-2, AI070535, AI113145, AI107779, AI124236, CCFA330251, AI125860, HL141999, NU 53/13-1
Related Journal Article